Back to Search
Start Over
Neuromuscular complications of immune checkpoint inhibitor therapy.
- Source :
-
Muscle & nerve [Muscle Nerve] 2018 Jan 17. Date of Electronic Publication: 2018 Jan 17. - Publication Year :
- 2018
- Publisher :
- Ahead of Print
-
Abstract
- Immune checkpoint inhibitor (ICPI) therapy unleashes the body's natural immune system to fight cancer. ICPIs improve overall cancer survival, however, the unbridling of the immune system may induce a variety of immune-related adverse events. Neuromuscular immune complications are rare but they can be severe. Myasthenia gravis and inflammatory neuropathy are the most common neuromuscular adverse events but a variety of others including inflammatory myopathy are reported. The pathophysiologic mechanism of these autoimmune disorders may differ from that of non-ICPI-related immune diseases. Accordingly, while the optimal treatment for ICPI-related neuromuscular disorders generally follows a traditional paradigm, there are important novel considerations in selecting appropriate immunosuppressive therapy. This review presents 2 new cases, a summary of neuromuscular ICPI complications, and an approach to the diagnosis and treatment of these disorders. Muscle Nerve, 2018.<br /> (© 2018 Wiley Periodicals, Inc.)
Details
- Language :
- English
- ISSN :
- 1097-4598
- Database :
- MEDLINE
- Journal :
- Muscle & nerve
- Publication Type :
- Academic Journal
- Accession number :
- 29342325
- Full Text :
- https://doi.org/10.1002/mus.26070